Title (SWOG S0805) Phase II Study of Combination of Hyper-CVAD and Dasatinib With or Without Allogenetic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)(A BMT Study)
Contact WWendy
Principal Investigator Meir Wetzler, MD
Study Number 203511
Phase2
Summary The purpose of this study is to find out what effects the investigational drug dasatinib has on Acute Lymphocytic Leukemia (ALL). Dasatinib is approved for use in the treatment of chronic myeloid leukemia and resistant Philadelphia chromosome positive ALL but is investigational as it is used on this study. The study would like to determine what effects of dasatinib in combination with drugs that are usually given as standard of care will have with or without a stem cell transplant.
Eligibility
- See Clinicaltrials.gov listing for Eligibility criteria.